Home/Filings/4/0001213900-25-028119
4//SEC Filing

Jordan Blair 4

Accession 0001213900-25-028119

CIK 0001690080other

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 4:59 PM ET

Size

8.7 KB

Accession

0001213900-25-028119

Insider Transaction Report

Form 4
Period: 2025-02-21
Jordan Blair
DirectorChief Executive Officer10% Owner
Transactions
  • Other

    Common Stock

    2025-02-21+200,000200,000 total(indirect: See footnote)
Holdings
  • Common Stock

    160,000
  • Common Stock

    (indirect: See footnote)
    43,166
Footnotes (4)
  • [F1]On February 5, 2025, the Issuer, the Reporting Person and Dr. James Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares or the date that the Issuer terminates the Voting Agreement. In order to enforce the terms of the Voting Agreement, Dr. Woody provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.
  • [F2]As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 43,166 shares of common stock of the Issuer held by Dr. Woody. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein.
  • [F3]On February 21, 2025, the Issuer, the Reporting Person and Dr. Marlene Krauss, entered into a Voting Agreement, whereby Dr. Krauss agreed to vote a total of 200,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to August 21, 2025. In order to enforce the terms of the Voting Agreement, Dr. Krauss provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 200,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.
  • [F4]As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 200,000 shares of common stock of the Issuer held by Dr. Krauss. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein.

Documents

1 file

Issuer

180 Life Sciences Corp.

CIK 0001690080

Entity typeother

Related Parties

1
  • filerCIK 0002015193

Filing Metadata

Form type
4
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 4:59 PM ET
Size
8.7 KB